ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.13 CNY | -1.57% |
|
-4.91% | -13.14% |
| May. 20 | Hisun Pharma's Veterinary Arm Gets Approval to Register Amoxicillin and Clavulanate Potassium Dry Suspension | MT |
| May. 16 | Hisun Pharma's Veterinary Arm Gets Nod to Market Selamectin Drops | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -13.14% | 1.34B | - | ||
| +37.78% | 705B | C+ | ||
| +32.82% | 583B | B | ||
| -3.51% | 364B | C+ | ||
| +19.94% | 332B | B- | ||
| +5.14% | 291B | C+ | ||
| +16.64% | 238B | B+ | ||
| -4.13% | 210B | A+ | ||
| +10.63% | 209B | B- | ||
| +9.32% | 169B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600267 Stock
- Ratings Zhejiang Hisun Pharmaceutical Co., Ltd.
